A Randomized, Multicenter, Phase II Trial of Cisplatin, Irinotecan and Bevacizumab (PCA) vs. Docetaxel, Cisplatin, Irinotecan and Bevacizumab (TPCA) in Metastatic Esophageal and Gastric Cancer.
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 13 Nov 2017
At a glance
- Drugs Docetaxel (Primary) ; Bevacizumab; Cisplatin; Irinotecan
- Indications Gastric cancer; Oesophageal cancer
- Focus Therapeutic Use
- 10 Oct 2017 Planned End Date changed from 1 Jun 2016 to 1 Jun 2018.
- 09 May 2016 Planned End Date changed from 1 Dec 2014 to 1 Jun 2016.
- 09 May 2016 Planned primary completion date changed from 1 Dec 2014 to 1 Jun 2016.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History